CD38 and plasma cell myeloma: Both Terpos et al. and Van Oeklen et al. have shown data that ongoing therapy particularly with anti‐CD38 antibodies and BCMA‐targeted therapy significantly reduced antibody responses in myeloma patients.9, 14